PNOC027Genomic Testing for Personalized Treatment in Relapsed Medulloblastoma and Ependymoma

This study is focused on creating personalized treatment plans for children and young adults who have experienced a relapse of two types of brain tumors: medulloblastoma and ependymoma. By using advanced techniques like drug screening and genetic testing, researchers aim to tailor a treatment plan that uses up to four existing FDA-approved drugs for each participant. The main goal is to see if these personalized plans can improve survival rates and safety compared to traditional treatments. This approach is important as it could lead to more effective and less harmful treatments for these patients, offering hope for better management of their conditions. Participants in the study will have tissue samples taken from their tumors, which are then analyzed using drug screening and genetic sequencing. Based on this analysis, a specialized team recommends a treatment plan tailored to the individual. Participants may continue this treatment for up to two years, or longer if it is beneficial. The study measures how long participants live without their disease progressing, as well as their overall survival. Safety and potential side effects are also closely monitored to ensure treatments are well-tolerated. The results could lead to more precise and effective therapies for relapsed brain tumors in young patients.